Velsera Seven Bridges Alternatives for Genomics Pipelines and Lab Workflows

Why bioinformatics teams start looking for a Velsera Seven Bridges alternative

The first trigger is cost visibility. Cloud genomics bills have two parts, the compute you consumed and the platform you consumed it through, and once sequencing volume grows the second part starts attracting attention from people who do not otherwise ask about bioinformatics. The question that follows is uncomfortable but reasonable: what exactly are we paying for on top of the cloud, and could we run these same tools directly.

The second trigger is access. Platform pricing tends to be shaped around seats or projects, and a research group wants twenty people poking at data, not four. Analysts who cannot get an account end up asking a bioinformatician to export files, and now your reproducibility story runs through someone's laptop. The third trigger is the last mile. The pipeline runs beautifully and then stops, and everything downstream, sample accessioning, interpretation, sign out, the report the ordering clinician actually reads, gets stitched together with spreadsheets and a shared drive. That gap is where most of the real operational pain sits, and it is not a pipeline problem at all.

What Seven Bridges genuinely does well

Reproducibility with provenance is the strongest argument. Workflows are versioned, executions are recorded, and you can answer the question that matters in any regulated or publication context: exactly which tool versions and parameters produced this result, on which inputs. Reconstructing that from a pile of shell scripts on a cluster is miserable, and teams who have tried do not want to try again.

The second strength is that it is a controlled environment for controlled data. Genomic data carries consent and access obligations, and a platform with managed access, audit logging and established security posture removes a large amount of governance work. Seven Bridges has long been one of the platforms behind major public research clouds, including the National Cancer Institute Cancer Genomics Cloud, which means the model has been exercised with real consortium scale data rather than only in vendor demos. Since the 2022 combination with Pierian and UgenTec under the Velsera name, the portfolio also reaches into clinical interpretation and reporting, which matters if you want one vendor from raw reads to signed report.

Third, it removes a genuine engineering burden. File management at terabyte scale, retry behaviour, spot instance handling, cost attribution per project: none of this is interesting work, all of it is required, and a hosted platform hands you a working answer on day one.

Where it actually strains

The first strain is portability. Workflow definitions written in a portable standard travel reasonably well, but everything around them, file organisation, metadata models, project structure and access rules, is specific to the platform. Leaving is therefore a bigger job than exporting files, and that asymmetry is worth understanding before your volumes grow rather than after.

The second is control over the compute layer. When you run a pipeline directly on your own cloud account you can pick instance types, use committed spend discounts and reserved capacity, tune parallelism, and see the bill by line. Through a platform, some of those levers move behind an interface, and optimisation becomes a support conversation instead of a configuration change.

The third is the shape of custom work. Any hosted platform builds what most customers need. If your assay is unusual, your pipeline needs a tool that is not packaged, or your interpretation workflow has a step nobody else runs, you are in a queue behind other customers. The fourth is the clinical last mile. Sign out workflow, report layout, ordering, laboratory information system and electronic health record interfaces vary between laboratories more than any vendor can economically support, so this is where most laboratories end up with a gap regardless of which platform they choose.

Your realistic options, including staying

Option one is another hosted platform. DNAnexus is the closest direct comparison and is widely used in both research and regulated settings. Terra, from the Broad Institute and Verily, is a strong research option, particularly for teams working with public datasets. Illumina Connected Analytics is the natural fit when your sequencing and secondary analysis already run on Illumina infrastructure. Lifebit and Form Bio serve federated and biotech oriented use cases respectively. Switching platform solves a pricing or fit complaint, and leaves the general shape of the relationship unchanged.

Option two is open source orchestration on your own cloud account. Nextflow with the nf core community pipelines is the most common answer, with Cromwell and workflow description language, Snakemake and Galaxy as established alternatives. You get portability, direct cloud pricing and full control of tool versions. You take on the operational burden: infrastructure, storage lifecycle, access control, monitoring and someone whose job includes it. For teams with even one capable cloud engineer, this is frequently the cheapest credible path.

Option three, and the one that solves the pain most laboratories actually describe, is a hybrid. Run pipelines on open source orchestration, and build the operational layer around them: accessioning, sample and batch tracking, quality control review, variant curation, sign out and reporting. Option four is staying, which is right more often than it sounds, particularly for small teams, teams inside a regulatory process, and teams whose real constraint is scientific rather than infrastructural.

When a custom build pays back

Build the workflow around the science, not the science itself. The strongest cases are a laboratory information layer that follows a sample from accessioning through extraction, library preparation, sequencing, analysis and report; a variant review and sign out interface shaped to how your directors actually work rather than how a generic tool assumes; a report generator producing the exact document your ordering clinicians expect; and integrations into the laboratory information system, electronic health record or ordering portal that no platform will build for one customer.

The economics are straightforward. That layer is used constantly by the same people, it encodes your specific operating procedures, and it is close to the service you sell. A platform cannot afford to build your version of it, and you cannot afford to run it on spreadsheets once volumes rise.

Do not rebuild aligners, variant callers or annotation tools. Those are solved, community maintained and validated by many groups, and writing your own is a research project rather than a product decision. Do not build if you have no cloud engineering capacity, because the operational tail lasts long after the build. And do not start a large custom project in the six months before a College of American Pathologists or Clinical Laboratory Improvement Amendments inspection.

Migration and validation reality

Migration in genomics is a concordance exercise, not a data copy. Export raw and processed files with checksums, workflow definitions and, most importantly, the metadata that links files to samples, subjects, consents and projects. Metadata is what teams underestimate, and it is the thing that turns a file archive back into usable data.

Then re run a representative set of samples through the new stack and compare outputs against the old. For research use, aim for documented concordance on variant calls across a mixed set including known difficult regions. For clinical use, expect a formal validation with reference materials, defined acceptance criteria and a signed report before anything moves. Keep the original environment available until validation is complete and any in flight studies have closed out, and keep archived results reachable for as long as your accreditation and consent terms require.

Cost bands

Hosted platform pricing is quoted and generally combines a platform component with cloud consumption, so ask for a model at three times your current sample volume rather than at today's. That is the number that decides whether you are comfortable in two years.

For custom work, based on what Digital Heroes delivers: a focused build, for example pipeline orchestration on your own cloud with sample tracking and a quality control dashboard, runs roughly $60k to $150k over 8 to 16 weeks. A full platform with accessioning, batch management, variant review, sign out and report generation runs roughly $180k to $400k, and clinical interfaces into a laboratory information system or electronic health record add to that. Cloud compute remains a separate operating cost either way, and running it directly usually costs less per sample than running it through a platform.

The honest verdict

Stay with a hosted platform if you are a small team without cloud engineering, if you depend on managed access to consortium datasets, or if you are inside a regulatory process where re validating your analysis stack right now would be reckless. Move to open source orchestration on your own cloud if your volumes have grown, your pipelines are standard and you have one person who can own infrastructure, because the savings are real and the portability is permanent. And if what actually hurts is everything after the pipeline finishes, build that layer. It is the part that is specific to your laboratory, and it is the part no vendor is going to build for you.